Kisqali

Ribociclib, the active ingredient in Kisqali, is a cyclin‑dependent kinase 4/6 inhibitor presented as an oral tablet for oral use. It treats hormone‑receptor‑positive, HER2‑negative advanced or metastatic breast cancer in combination with endocrine therapy.

GNH USA supplies Kisqali as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Kisqali is a CDK4/6 inhibitor used in the management of hormone‑receptor‑positive breast cancer pathways.

Hormone receptor‑positive, HER2‑negative advanced breast cancer: improves progression‑free survival when combined with endocrine therapy. Premenopausal women with HR+/HER2‑negative advanced breast cancer: used together with ovarian suppression and endocrine agents. Postmenopausal women with HR+/HER2‑negative metastatic breast cancer: administered alongside aromatase inhibitors for disease control.

Ribociclib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced neutrophil count, increasing infection risk. - Nausea: mild to moderate upset stomach. - Fatigue: persistent tiredness. - Diarrhea: loose stools. - Alopecia: hair thinning or loss. - Vomiting: occasional episodes.

Serious or Rare Side Effects: - QT interval prolongation: potential cardiac rhythm disturbances. - Severe neutropenia: marked drop in neutrophils requiring medical attention. - Hepatotoxicity: elevated liver enzymes or liver injury. - Interstitial lung disease: rare pulmonary inflammation. - Severe infections: opportunistic bacterial or fungal infections. - Thromboembolic events: rare blood clot formation.

Before initiating ribociclib therapy, several safety considerations should be addressed.

Monitor blood counts: perform regular CBC to detect neutropenia. Assess cardiac function: obtain baseline ECG and monitor QT interval. Evaluate liver function: check hepatic enzymes prior to and during treatment. Avoid strong CYP3A4 inhibitors: these can increase ribociclib exposure. Pregnancy and lactation: contraindicated; advise effective contraception. Store at ambient temperature: keep tablets in the original container, protect from moisture and direct sunlight.

Ribociclib may interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can raise ribociclib levels. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect. - QT‑prolonging agents (e.g., certain antiarrhythmics): increase risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): may modestly increase exposure. - Moderate CYP3A4 inducers (e.g., phenytoin, St. John’s wort): could lower drug concentrations. - Endocrine therapies (e.g., aromatase inhibitors): monitor for additive toxicities. - Antacids containing multivalent cations: may affect absorption; separate dosing times.